Introduction {#Sec1}
============

Since the commercialization of the new antimigraine drug sumatriptan about 20 years ago, scientific societies, pharmaceutical companies and headache specialists, have tried to highlight the migraine pathology in the population, arguing that it was underestimated. In the following years many other drugs, in the pharmacological class of triptans, became available.

The average percentage of migraine in the world is regarded as around 9% of the overall population \[[@CR1]\]. However, until today, migraine remains under-diagnosed and under-treated in at least 50% of patients, and less than 50% of migraine patients had consulted a physician \[[@CR1], [@CR2]\]. The efficacy of triptans has been shown in several randomized, double-blind, placebo-controlled trials \[[@CR3]\]. However these studies were carried out in selected populations and under controlled conditions. Utilization patterns of specific anti-migraine drugs in community patients and the experiences of patients with these drugs in real life setting have been studied less extensively. Recently we have performed a study evaluating triptans utilization in a health authority in Tuscany covering about 225,000 residents \[[@CR4], [@CR5]\]. We have extended this study to establish the patterns of use of triptans in a large sample of Italian population \[[@CR6]\] and review other studies on this topic.

Materials and methods {#Sec2}
=====================

Study on the Italian population {#Sec3}
-------------------------------

In the reimbursement system of the Italian National Health Service, all prescribed drugs included within the essential level of assistance (LEA) are recorded by regional health authorities in association with the demographic characteristics of patients. Therefore, medication records of individual patients are quite complete in drugs prescription databases. This allows for accurate investigations in drug utilization in our setting. The patterns of triptans prescription in the 33 health authorities distributed in 8 Italian regions were investigated. The population studied was 5.57 millions inhabitants, that represents 9.5% of the Italian population. We analysed prescription database using the ATC classification (Anatomical Therapeutic Chemical classification) NO2CC: triptans, dispensed during 1 year (2006).

In Italy each prescription of triptans could contain one or two packages. In 2006, all triptans (except naratriptan) were available as oral tablets in Italy, for rizatriptan and zolmitriptan as soluble oral tablets, sumatriptan as subcutaneous injections, nasal spray and rectal suppositories. The doses contained in each package of triptans available in Italy are reported in Table [1](#Tab1){ref-type="table"}. Table 1Dosage units contained in triptans packages available in Italy in 2005--2006TriptansPackagesDosage unitsSumatriptanTablet 50--100 mg4SumatriptanSuppository 25 mg2SumatriptanNasal spray 10--20 mg2SumatriptanInjection 6 mg2ZolmitriptanTablet 2.5 mg3ZolmitriptanSoluble tablet 2.5 mg2RizatriptanTablet 5--10 mg3RizatriptanSoluble tablet 10 mg3EletriptanTablet 20--40 mg3AlmotriptanTablet 12.5 mg3FlovatriptanTablet 2.5 mg2FlovatriptanTablet 2.5 mg6

Literature review {#Sec4}
-----------------

Studies were identified through a Medline search on Internet (Pubmed Medline, 2000 version; address <http://www4.ncbi.nlm.nih.gov/PubMed/>). This search covered the period from 1991 to June 2007.

Results {#Sec5}
=======

Study on the Italian population {#Sec6}
-------------------------------

Demographic characteristics of the population studied are reported in Table [2](#Tab2){ref-type="table"}. Table 2Demographic characteristics of the population studiedAgeMalesFemalesTotal0--14370,058348,222718,28015--441,141,6061,108,1992,249,80545--64697,013722,0451,419,05865--74280,037329,408609,44575--84169,295258,847428,142\>8538,35886,643125,001Total2,696,3672,853,3645,549,731

On a total of 5,549,731 resident population, the subjects that received triptans were 32,584 (0.6% of the population), 22.3% males and 77.7% females. Males and females aged 15--44 represented 51.4% of total users, while those aged 45--65 were 38.7%. The patients aged over 65 years were 9.5%. The total number of triptan packages prescribed was 312,337 (Table [3](#Tab3){ref-type="table"}). We found the higher dosage (DDD/1,000 inhabitants/day, DDD = defined daily dose) in the 45--64 years group. The DDD/1,000 inhabitants/day was: 0.004 (0--14 years), 0.813 (15--44 years), 1.324 (45--64 years), 0.446 (65--74 years), 0.216 (75--84 years), 0.122 (\>85 years). Table 3Pattern of triptans utilization in a sample of 5,549,731 Italian residentsAgeUsers (%)Packages (%)DDD/1,000 inhabitants/day0--140.20.080.00415--4451.446.10.81345--6438.745.51.32465--746.25.90.44675--842.71.90.216\>850.60.30.122Total (no.)32,584312,337*DDD*defined daily dose

The distribution of triptan packages prescribed was: rizatriptan 26%, sumatriptan 20.1%, almotriptan 17.3%, zolmitriptan 13.9%, eletriptan 12.6%, frovatriptan 10%.

Literature review {#Sec7}
=================

Prevalence of triptan users {#Sec8}
---------------------------

A prescription register survey in Denmark revealed that nearly 1% of the population recurred to sumatriptan in 1-year period \[[@CR7]\]. Other studies describing the percentage of triptan users, in periods when more triptans are available, are reported in Table [4](#Tab4){ref-type="table"} \[[@CR5], [@CR6], [@CR8]--[@CR15]\]. The prevalence of triptan users in a year period was 0.55--1.4%. Some of these studies \[[@CR8], [@CR12], [@CR13]\] were performed on new users of triptans who were defined as patients who had not received any triptan in the period preceding the study. The new users account for 25--63% of total users, depending on the period of study and the period considered without assumption preceding the study (Table [5](#Tab5){ref-type="table"}). Table 4Prevalence of triptans users in population studiesStudyCountry/YearPopulationUsersPeriodPercentageFemales (%)Etemad^c^ \[[@CR8]\]USA 1998--2000\>2,000,0008,4881 year\<0.4283.6Lohman^a^ \[[@CR9]\]Netherlands 2001--2002168,0002,3431 year1.478Perearnau \[[@CR10]\]France 2003--20041,793,00020,6861 year1.1578.5Pavone \[[@CR5]\]Italy 2005224,0651,2381 year0.5577.9Dekker \[[@CR11]\]Netherlands 20056,700,00085,1721 year1.27NRPanconesi \[[@CR6]\]Italy 20065,549,73132,5841 year0.677.7Ifergane^c^ \[[@CR12]\]Israel 2003--2004500,0001,4981 year0.377.1Lugardon^c^ \[[@CR13]\]France 20021,550,00013,8606 months1.080.6Sondergaard \[[@CR14]\]Denmark 2000472,0002,4633 months0.5282.7Hoffman^b^ \[[@CR15]\]USA 1999600,0004,7183 months0.78NR*NR* not reported^a^enclosed also ergotamine, ^b^enclosed also dihydroergotamine nasal spray, ^c^new usersTable 5Percentage of new users of triptansStudyAntecedent periodStudy periodPopulationTotal usersNew usersNew users (%)Lugardon^a^ (France 2002) \[[@CR13]\]6 months6 months1,550,00013,8608,62563Sondergaard (Denmark 2000) \[[@CR14]\]9 months3 months472,0002,46361725Etemad (USA 1988) \[[@CR8]\]6 months1 year2,000,0008,4885,38363^a^among new users, half were occasional users, with only a single prescription during 1 year period

The prevalence of triptans utilization in migraine patients in different countries was reported to be 3--19% (average 10%) \[[@CR1]\], while other population studies show a similar prevalence: 7.5% \[[@CR16]\], 8% \[[@CR17]\], 9.8% \[[@CR18]\]. Therefore the percentage of triptan utilization in the population has a good relation to the pathology, showing that less than 10% of patients use a triptan.

Migraine patient referred to headache clinics, increase the rate of triptans assumption after consultation \[[@CR19], [@CR20]\].

Frequency of triptan use {#Sec9}
------------------------

About 40--60% of triptans users received only one prescription in 1 year (Fig. [1](#Fig1){ref-type="fig"}). Single users of sumatriptan were also reported to be over 40% \[[@CR21], [@CR22]\]. Fig. 1Percentage of patients receiving only one triptan prescription during 1 year. \* New users

Lohman et al. \[[@CR9]\] report that 12.5% of triptan users utilized more than one drug product and received 25% of the total number of dosage units. Ifergane et al. \[[@CR12]\] report that, among patients who filled more than one prescription, 14.3% tried a second triptan; in this group 52.1% purchased only one prescription of the new triptan. Tepper et al. \[[@CR23]\] showed that 91% of the patients remained on the same triptan during the study period. In conclusion 10--15% of triptans users change the type of triptan during the period of 1 year.

On the other hand, a minority of triptan users utilize a large percentage of annual triptan prescriptions (Table [6](#Tab6){ref-type="table"}). A population study in Denmark too showed that a minority of sumatriptan users (5%) were taking this medication on a daily basis accounting for 38% of all sumatriptan use \[[@CR7]\]. Table 6Few patients (%) of total triptan users consume a large percentage of the triptans prescribed in a yearStudyPatients (%)Consumption (%)Perearnau (France 2003) \[[@CR10]\]7.943.6 of intakesDekker (Netherlands 2005) \[[@CR11]\]10.446 of costPavone (Italy 2005) \[[@CR5]\]5.740 of packages or 44 of DDDs*DDD* defined daily dose

A comparison of intensity of triptan utilization in different countries cannot be performed considering the number of triptan packages, because triptan packages may contain different number of doses depending on marketing policies. Then a comparison of studies must be performed considering doses or DDD (Table [7](#Tab7){ref-type="table"}). Table 7Month frequency of triptan assumptionPavone (2005 Italy) \[[@CR5]\]1.8DDDs (mean)Perearnau (2003 France) \[[@CR10]\]2.1Doses (mean)Sondergaard (2000 Denmark) \[[@CR14]\]2.7--3.3Doses (median)Lohman (2001 Netherlands) \[[@CR9]\]2.9Doses (mean)Tepper (2002 USA) \[[@CR23]\]4.2 ♂--4.6 ♀Doses (mean)*DDD* defined daily dose

Initial studies on triptan abuse concerned sumatriptan \[[@CR7], [@CR24]\]. The critical intake frequency for patients with triptan overuse headache, is reported to be 18 single doses of triptans per month \[[@CR25]\]. Then, considering 216 tablets/year as critical doses for triptan overuse, the percentage of patients overusing triptans are 0.9--3.3% of all triptans users (Table [8](#Tab8){ref-type="table"}). However, ten single dosages per month (120 doses/year) may be sufficient to cause triptans overuse headache and therefore should be considered a critical threshold \[[@CR25], [@CR26]\]. Therefore, in various studies 3.2--11.9 of patients are possible triptan abusers (Table [8](#Tab8){ref-type="table"}). We cannot classify these patients as suffering of triptan-overuse headache, that is with code 8.2.2 of the International Headache Society (IHS) classification \[[@CR26]\], because we do not know their clinical characteristics (headache present on \>15 day/month, with frequency increased during triptan overuse and impaired within 2 months after triptan discontinuation) and the number of days of triptans intake. However, these patients are probably at risk for developing triptans-overuse headache or rather they already developed this chronic headache. Table 8Percentage of probable triptans abusers among triptan usersStudyCriteria%Sondergaard (Denmark 2000) \[[@CR14]\]\>15 DDD/m4.7Lugardon (France 2002) \[[@CR13]\]15--29 DDD/m10.0\>29 DDD/m1.9Lohman (Netherlands 2001) \[[@CR9]\]\>120 DDD/y5.0\>216 DDD/y1.9Dekker (Netherlands 2005) \[[@CR11]\]\>120 DDD/y10.4\>216 DDD/y3.3Pavone (Italy 2005) \[[@CR5]\]\>120 DDD/y3.2\>216 DDD/y0.9Perearnau (France 2003) \[[@CR10]\]\>144 DDD/y1.9*DDD* defined daily dose, *m* month, *y*year

A consistent percentage of triptans is prescribed for people over the age of 65. In the Italian population this percentage is 7.6--9.5% \[[@CR5], [@CR6]\], higher than that reported (3.2--3.5%) in the France population \[[@CR10], [@CR27]\]. A previous study shows that sumatriptan users over 65 years were 3% \[[@CR28]\]. This is a population at major risk of hypertension and cardiovascular diseases, and it is also a population in which clinical trials have been not performed and so triptans are not recommended.

Discussion {#Sec10}
==========

The main conclusions coming from these studies are:A very low percentage (about 10%) of migraine patients utilized triptans.When utilized, triptans were prescribed only once in a year in a large percentage (40--60%) of patients.A minority of patients (5--10%) utilize a large amount (40--45%) of triptans, and some of these are classified as triptans abusers.A considerable percentage of triptans are prescribed in people aged over 65.The low percentage of triptans users can be due to the low rate of diagnosis of migraine and the high utilization of over-the-counter drugs (OTC). Less than 50% of people suffering from migraine are not recognized by their general practitioner as having migraine and less than 30% of these have adequate management of migraine \[[@CR29]\]. Possible causes of underdiagnosis and management by general practitioner are: poor time to spend with the patient, complexity of diagnostic criteria of IHS \[[@CR26]\], variability of the clinical manifestations in migraine patients \[[@CR30], [@CR31]\], high utilization of OTC drugs \[[@CR1]\], and high cost of triptans.The high percentage of single prescriptions of triptans could indicate that many migraine patients had low frequency of attacks; in fact it was reported that only 20% patients had more than 14 migraine days per year \[[@CR32]\]. Other studies reported an higher frequency: 75% of migraine patients have 0--3 attacks/months and 25% more than one attack/week \[[@CR2], [@CR17]\]. Another interpretation of the low percentage and frequency of triptans use is that many migraine patients cannot completely control migraine by triptans therapy because of lack of efficacy and/or side effects. Rahimtoola et al. \[[@CR28]\] found that the main reasons for discontinuing treatment after only one prescription, was inefficacy and/or the occurrence of side effects. Maybe some patients tested a triptan but thereafter they do not require it again. This assumption was supported by the fact that although new triptan users are a large proportion of total users, the percentage of triptans users during the years has remained low. There are reports showing that an important subset of triptan users is dissatisfied with their usual care and about 80% would be willing to try another acute medication \[[@CR33]\].
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